Eli Lilly and Co plans to submit a marketing application for efsitora for the treatment of adult patients with type 2 diabetes by the end of this year.

On June 22, Eli Lilly and Co announced detailed results from three Phase 3 clinical studies: QWINT-1, QWINT-3, and QWINT-4. These studies evaluated the efficacy and safety of once-weekly efsitora alfa (efsitora) in adult patients with type 2 diabetes (T2DM) who were initiating insulin therapy, those who had previously used daily basal insulin therapy, and those who had previously used a combination of basal insulin and mealtime insulin. All studies achieved their primary endpoints, demonstrating that once-weekly efsitora was non-inferior to daily basal insulin in reducing hemoglobin A1C (A1C) levels. Eli Lilly and Co plans to submit a marketing application for efsitora for the treatment of adult patients with type 2 diabetes to global regulatory authorities by the end of this year.